CorMedix Statistics
Total Valuation
CorMedix has a market cap or net worth of $596.84 million. The enterprise value is $593.13 million.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CorMedix has 78.43 million shares outstanding. The number of shares has increased by 36.41% in one year.
| Current Share Class | 78.43M |
| Shares Outstanding | 78.43M |
| Shares Change (YoY) | +36.41% |
| Shares Change (QoQ) | +8.94% |
| Owned by Insiders (%) | 7.18% |
| Owned by Institutions (%) | 47.19% |
| Float | 67.51M |
Valuation Ratios
The trailing PE ratio is 3.72 and the forward PE ratio is 13.57.
| PE Ratio | 3.72 |
| Forward PE | 13.57 |
| PS Ratio | 1.93 |
| Forward PS | 1.93 |
| PB Ratio | 1.53 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.49 |
| P/OCF Ratio | 3.45 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 3.39, with an EV/FCF ratio of 3.43.
| EV / Earnings | 3.66 |
| EV / Sales | 1.90 |
| EV / EBITDA | 3.39 |
| EV / EBIT | 3.70 |
| EV / FCF | 3.43 |
Financial Position
The company has a current ratio of 2.11, with a Debt / Equity ratio of 0.37.
| Current Ratio | 2.11 |
| Quick Ratio | 1.83 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 0.85 |
| Debt / FCF | 0.86 |
| Interest Coverage | 57.64 |
Financial Efficiency
Return on equity (ROE) is 66.56% and return on invested capital (ROIC) is 36.73%.
| Return on Equity (ROE) | 66.56% |
| Return on Assets (ROA) | 21.21% |
| Return on Invested Capital (ROIC) | 36.73% |
| Return on Capital Employed (ROCE) | 24.60% |
| Weighted Average Cost of Capital (WACC) | 9.91% |
| Revenue Per Employee | $1.63M |
| Profits Per Employee | $848,518 |
| Employee Count | 191 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | -13.04M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.26% in the last 52 weeks. The beta is 1.41, so CorMedix's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -16.26% |
| 50-Day Moving Average | 6.97 |
| 200-Day Moving Average | 9.90 |
| Relative Strength Index (RSI) | 59.57 |
| Average Volume (20 Days) | 981,869 |
Short Selling Information
The latest short interest is 15.72 million, so 20.04% of the outstanding shares have been sold short.
| Short Interest | 15.72M |
| Short Previous Month | 15.78M |
| Short % of Shares Out | 20.04% |
| Short % of Float | 23.29% |
| Short Ratio (days to cover) | 13.34 |
Income Statement
In the last 12 months, CorMedix had revenue of $311.71 million and earned $162.07 million in profits. Earnings per share was $2.04.
| Revenue | 311.71M |
| Gross Profit | 289.62M |
| Operating Income | 160.34M |
| Pretax Income | 150.02M |
| Net Income | 162.07M |
| EBITDA | 174.89M |
| EBIT | 160.34M |
| Earnings Per Share (EPS) | $2.04 |
Full Income StatementBalance Sheet
The company has $148.53 million in cash and $148.91 million in debt, with a net cash position of $9.98 million or $0.13 per share.
| Cash & Cash Equivalents | 148.53M |
| Total Debt | 148.91M |
| Net Cash | 9.98M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 405.31M |
| Book Value Per Share | 5.11 |
| Working Capital | 192.78M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $175.05 million and capital expenditures -$2.26 million, giving a free cash flow of $172.79 million.
| Operating Cash Flow | 175.05M |
| Capital Expenditures | -2.26M |
| Depreciation & Amortization | 14.55M |
| Net Borrowing | 149.81M |
| Free Cash Flow | 172.79M |
| FCF Per Share | $2.20 |
Full Cash Flow StatementMargins
Gross margin is 92.91%, with operating and profit margins of 51.44% and 52.31%.
| Gross Margin | 92.91% |
| Operating Margin | 51.44% |
| Pretax Margin | 48.13% |
| Profit Margin | 52.31% |
| EBITDA Margin | 56.11% |
| EBIT Margin | 51.44% |
| FCF Margin | 55.43% |
Dividends & Yields
CorMedix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -36.41% |
| Shareholder Yield | -36.41% |
| Earnings Yield | 26.87% |
| FCF Yield | 28.65% |
Analyst Forecast
The average price target for CorMedix is $14.83, which is 94.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.83 |
| Price Target Difference | 94.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 14.75% |
| EPS Growth Forecast (5Y) | 12.79% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on March 26, 2019. It was a reverse split with a ratio of 1:5.
| Last Split Date | Mar 26, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
CorMedix has an Altman Z-Score of 2.13 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.13 |
| Piotroski F-Score | 5 |
